Empator L 10mg/5mg Tablets (14s)

Description

Empator L is a prescription fixed-dose combination tablet containing empagliflozin and linagliptin for improving blood glucose control in adults with type 2 diabetes mellitus. It is used together with diet and exercise, alone or with other diabetes medicines as directed by a healthcare professional.

• Manufacturer Name: Martin Dow
• Drug Class: SGLT2 inhibitor and DPP-4 inhibitor combination antidiabetic
• Dosage Form: Tablet
• Storage: Store at room temperature, generally below 30°C, in the original packaging. Protect from moisture, heat, and direct light; keep out of reach of children.
• Pack Size: Pack of 14 Tablets

Empator L 10mg/5mg Tablets (14s) Available Online in Pakistan

Dwatson offers Empator L 10mg/5mg Tablets (14s) at Rs. 504, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 10 mg
• Linagliptin 5 mg

Benefits

• Improves blood glucose control in adults with type 2 diabetes mellitus.
• Used with diet and exercise when additional glycemic control is needed.
• May be used alone or with other glucose-lowering medicines, including metformin, insulin, or a sulfonylurea, when prescribed.

Usage & Safety

For Adult

• The usual dosage is one tablet once daily, taken orally, with or without food.
• Take at the same time each day and swallow the tablet whole with water.
• Maintain adequate fluid intake unless fluid restriction has been advised.
• Dosage selection should consider kidney function, current diabetes treatment, hydration status, and risk of hypoglycemia.
• Do not stop or change the dose without medical advice.

For Children

• Safety and effectiveness of this fixed-dose combination in children and adolescents have not been adequately established.
• It is generally not recommended for patients under 18 years unless specifically prescribed and monitored by a specialist.
• There is no established weight-based pediatric dose for this product.

Side Effects

• Common effects may include increased urination, thirst, genital fungal infection, urinary tract infection, nausea, dizziness, or mild gastrointestinal discomfort.
• Low blood glucose is more likely when used with insulin or sulfonylureas.
• Empagliflozin may cause dehydration, low blood pressure, reduced kidney function, or electrolyte disturbances.
• Seek urgent medical attention for symptoms of ketoacidosis such as nausea, vomiting, abdominal pain, unusual tiredness, difficulty breathing, or confusion, even if blood glucose is not very high.
• Report severe genital or perineal pain, swelling, redness, fever, pancreatitis-like severe abdominal pain, facial swelling, or difficulty breathing immediately.

Contraindications

• Do not use in patients with known allergy or hypersensitivity to empagliflozin, linagliptin, or any product ingredient.
• Not intended for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
• Avoid use in patients with end-stage kidney disease, dialysis, or severe renal impairment unless specifically directed by a specialist.
• Use caution in patients with dehydration, low blood pressure, recurrent urinary or genital infections, pancreatitis history, or significant kidney disease.
• Temporarily discontinue and seek medical advice during major surgery, prolonged fasting, or serious acute illness when ketoacidosis risk may increase.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia; their doses may need adjustment by a clinician.
• Diuretics may increase the risk of dehydration, low blood pressure, and kidney problems.
• Other medicines that lower blood glucose may enhance the glucose-lowering effect.
• Strong CYP3A4 or P-glycoprotein inducers may reduce linagliptin exposure and effectiveness.
• Alcohol may worsen dehydration and may increase the risk of abnormal blood glucose or ketoacidosis, particularly during illness or reduced food intake.
• Tell the healthcare professional about all prescription medicines, over-the-counter products, and herbal supplements before use.

Pregnancy

• Use during pregnancy only if specifically prescribed after medical assessment; alternative treatment may be preferred, particularly during the second and third trimesters.
• Empagliflozin may affect fetal kidney development based on its mechanism and available non-human data.
• Breastfeeding is generally not recommended during treatment because potential effects on the developing infant kidney cannot be excluded.
• Patients who are pregnant, planning pregnancy, or breastfeeding should consult their healthcare professional before using this medicine.